Cite
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies
MLA
Donald A. Richards, et al. “Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.” Cancer Management and Research, Aug. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....302a79f6b1f9ddbdbd908703851c2717&authtype=sso&custid=ns315887.
APA
Donald A. Richards, J. Thaddeus Beck, Rajesh K. Malik, Joyce M Antal, Ivan Sinielnikov, Keith Lerro, Marielle Sabatini, Maen A. Hussein, Marina Maglakelidze, Alexander I. Spira, Todd A Gersten, & Yili Pritchett. (2021). Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research.
Chicago
Donald A. Richards, J. Thaddeus Beck, Rajesh K. Malik, Joyce M Antal, Ivan Sinielnikov, Keith Lerro, Marielle Sabatini, et al. 2021. “Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.” Cancer Management and Research, August. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....302a79f6b1f9ddbdbd908703851c2717&authtype=sso&custid=ns315887.